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Summary 
Intracellular proteases appear to be important mediators of apoptosis. Substrates cleaved by pro- 
teases during apoptosis include nuclear autoantigens targeted in systemic autoimmune diseases. 
Using human autoantibodies as probes, we demonstrate here that T  cell apoptosis mediated by 
CD95 (Fas/APO-1) is associated with substantial cleavage of a subset of nuclear autoantigens (7 
of 33 examined). This subset included poly (ADP-ribose) polymerase, the 70-kD protein of the 
U1  small nuclear  ribonucleoprotein  particle,  lamin B,  the  nuclear  mitotic  apparatus protein 
NuMA,  DNA topoisomerases I  and II, and the l<NA polymerase I  upstream binding factor 
UBF.  Several of the  cleaved autoantigens  are  involved in  ensuring the  integrity and  proper 
conformation of DNA in the nucleus through interactions with the nuclear matrix, suggesting 
the possibility that  their  cleavage may contribute  to  the  collapse of nuclear structure  during 
apoptosis. The relative cleavage kinetics indicated that the autoantigens were targeted at vari- 
ous times after induction of apoptosis, suggesting either differential accessibility or activation of 
distinct proteases during the cell death process. These data reinforce the hypothesis that apop- 
tosis is accompanied by selective cleavage of key substrates and not by a generalized degrada- 
tion of intracdlular material. 
T 
he activation of proteases is an important event in the 
control  of  apoptosis  (1).  These  proteases  include 
members of the interleukin-l[3-converting enzyme (ICE)/ 
CED-3  family,  serine  proteases,  calpains,  and  granzymes 
(1).  Major  challenges  in  the  analysis  of proteolytic events 
associated  with  apoptosis  are  to  define  the  mechanisms 
leading to protease activation, to characterize the different 
protease activities acting at various stages of apoptosis, and 
to identify key substrates whose  cleavage might be linked 
to the profound changes in cellular architecture  associated 
with this cell death process. Among the substrates cleaved 
during  apoptosis are  nuclear  autoantigens  targeted  in  sys- 
temic  autoimmune  diseases  such  as  poly  (ADP-ribose) 
polymerase (PAl<P)  (2,  3),  the  70-kD  component of the 
U1  small  nuclear  ribonucleoprotein  particle  (U1-70  kD) 
(4),  the  nuclear lamins  (5,  6),  the nuclear  matrix and mi- 
totic apparatus protein NuMA (7, 8), and DNA-dependent 
protein  kinase  (9).  It has been  suggested that  cleavage of 
certain  autoantigens  during  apoptosis  may  reveal  immu- 
nocryptic  epitopes that could potentially induce  autoanti- 
body responses in systemic autoimmune diseases  (9). In this 
study  we  used  human  autoantibodies  as  probes  for  the 
identification  of  substrates  cleaved  during  CD95  (Fas/ 
APO-1)-mediated  T  cell  apoptosis.  CD95-mediated  cell 
death is involved in the regulation of immune reactions as 
well  as in  T  cell-mediated  cytotoxicity (10).  The impor- 
tance  of this  cell  death  pathway in  immune  regulation  is 
underscored by the demonstration that defects in the genes 
encoding CD95 and its ligand, CD95 L, are associated with 
autoimmune lymphoproliferative disorders in  certain mu- 
rine strains and in humans (10).  Here we show that CD95- 
mediated apoptosis is accompanied by selective targeting of 
nuclear autoantigens by proteases acting at different stages 
of the cell death process. 
Materials and Methods 
Cell Lines and Reagents.  Jurkat and A1.1 cells (American Type 
Culture  Collection,  Rockville,  MD)  were  cultured  in  RPMI 
1640/10%  fetal bovine serum under standard  conditions.  Anti- 
CD95/Fas mAb CH-11 was purchased  from Medical  and Bio- 
logical  Laboratories  (Watertown,  MA).  Anti-CD3  mAb  (145- 
2Cll)  was  purified  as  described  (11). Human sera  containing 
highly specific, high titer autoantibodies  to well characterized in- 
tracellular proteins  were from the collection  of the W.M. Keck 
Autoimmune Disease Center Laboratory serum bank. These sera 
were previously characterized by immunodlffusion,  immunofluo- 
rescence microscopy,  and immunoblotting in several studies per- 
formed in our laboratory.  Rabbit antibody R29 reactive against 
the oL and [3 isoforms of DNA topoisomerase  II was kindly pro- 
vided by Dr. F.H. Drake (SmithKline Beecham, King of Prussia, 
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vided by Dr.  Robert  L.  Ruhin  (Scripps  Research  Institute,  La 
Jolla, CA). 
Induction of Apoptosis.  Apoptosis was induced in Jurkat T cells 
by incubation with anti-CD95 mAb CH-11 at a final concentra- 
tion of 100 ng/ml for up to 7 h. To minimize spontaneous apop- 
tosis before incubation with anti-CD95  mAb, cell cultures were 
maintained in  exponential growth by dilution  in fresh medium 
every 2-3 d. Jurkat cells were also induced to undergo apoptosis 
by exposure to cycloheximide (75 I.tM), C2-ceramide (40 ~M), 
actinomycin D  (10 ~M), etoposide (150 ~M), and staurosporine 
(2 btM) for t2 h. C2-ceramide was purchased from Biomol (Hy- 
mouth Meeting,  PA).  Staurosporine,  etoposide (VP-16), actino- 
mycin D, and cycloheximide were purchased from Sigma Chem- 
ical Co. (St. Louis, MO). A1.1  cells, a murine T  cell hybridoma, 
were induced to undergo apoptosis by culturing in wells  coated 
with an anti-CD3 mAb as previously described (11). Morpholog- 
ical changes associated  with apoptosis, such as cell shrinkage, nu- 
clear  condensation  and  fragmentation,  and  plasma  membrane 
blebbing were routinely monitored by light microscopy. Apop- 
totic cells were quantitated by fluorescence microscopic visualiza- 
tion of nuclei stained with 4',6-diamidino-2-phenylindole (DAPI). 
Electrophoresis and Western Blotting of Cell Lysates.  Cells  were 
pelleted at  1,000 g for 10 min, followed by two washes in PBS 
containing the COMPLETE Protease Inhibitor Cocktail (Boeh- 
ringer  Mannheim,  Germany).  Cells  were  then  resuspended  at 
~10 v cells/nil in lysis buffer containing 62.5 mM Tris-HC1, pH 
6.8,  1% SDS,  10% glycerol,  1% mercaptoethanol, and the pro- 
tease inhibitor cocktail. Lysates were boiled for 5 min to solubi- 
lize protein, passed through a 27-gauge needle to shear the DNA, 
and  stored  at  -70~  until  required.  Cell  harvesting and lysate 
preparation were conducted in the presence of the protease in- 
hibitor cocktail as a precaution to prevent further proteolysis. To- 
tal  protein  from r  cells  were  separated by sodium  dodecyl 
sulfate-polyacrylamide gel  electrophoresis and transferred to  ni- 
trocellulose at 250 mA for 4-5 h. Immunoblotting was performed 
using standard procedures and detection of bound antibody was 
achieved by the  enhanced  chemiluminescence  method  (Amer- 
sham, Life Science, IL). Human sera were used at dilutions rang- 
ing from 1:100  to  1:500,  depending on the antibody titer of the 
individual serum. 
Results 
Cleavage  of a Subset of Nuclear Autoantigens  during CD95- 
mediated Apoptosis.  33 different autoantigens associated with 
various subceUular structures  and functions  were examined 
by immunoblotting analysis oflysates from control and apop- 
totic Jurkat cells.  Cells were induced  to undergo  apoptosis 
by incubation with anti-CD95  mAb (100 ng/ml). Approx- 
imately  60%  of treated  cells  displayed  the  characteristic 
apoptotic  morphology  after  7  h  of incubation  with  anti- 
CD95 mAb, as assessed by fluorescence microscopic exam- 
ination  of DAPI-stained  nuclei  (data  not  shown).  DNA 
fragmentation  was visible 2  h  after addition  of anti-CD95 
antibody to cell cultures  (data not shown). 
Of I2 chromatin  or DNA-associated  proteins  that were 
examined,  PARP,  DNA  topo  I,  DNA  topo  II,  NuMA, 
and lamin B  (Table  1 and  Fig,  1 A)  underwent  substantial 
cleavage during  apoptosis,  as judged  by the  appearance  of 
lower molecular mass bands in the blots concomitant  with 
a proportional  reduction  in  the  amount  of the intact pro- 
tein.  PARP  cleavage  generated  the  signature  85-kD  frag- 
ment  reported  previously  (2,  3).  DNA  topo  l  cleavage 
yielded  a  70-kD  fragment.  DNA  topoisomerase  II  (both 
the ee and [3 isoforms) underwent  extensive proteolysis that 
yielded  several  lower  molecular  mass  fragments  (Table  1; 
also see Fig. 2). NuMA,  a nuclear matrix protein of 236 kD 
implicated in the  organization  of chromatin  into loops via 
binding to specialized DNA sequences termed MAPs (matrix 
attachment  regions)  (12),  underwent  complete  proteolysis 
that yielded  two  fragments  of ~180  and  160  kD,  respec- 
tively  (Fig.  1  A).  Lamin  B,  a  nuclear  envelope  and  also 
MAR-associated autoantigen  (12) was cleaved into the sig- 
nature  45-kD  fragment  reported  previously  (5,  6)  (Fig.  1 
A).  Non-cleaved  DNA/chromatin-associated  autoantigens 
included  PCNA,  Ku,  centromere  proteins  CENP  A, 
CENP  B,  CENP  C,  histone  H2B,  and  heterochromatin 
binding  protein  HP-1  (Fig.  1  and  data  not  shown).  Of 3 
autoantigens associated with pre-mRNA splicing that were 
examined  only U1-70  kD  underwent  substantial  cleavage, 
yielding the 40-kD signature fragment described previously 
(4)  (Fig.  1 B).  None  of the components of the Sm splicing 
particle  were  cleaved  (Fig.  1  B).  HCC1,  a  putative  SR 
family splicing factor, was not cleaved (data not shown).  Of 
5  nucleolar-associated  autoantigens  examined  (fibrillarin, 
B23/numatrin,  To,  PM-Scl,  and  UBF/NOR-90),  only 
UBF underwent substantial proteolysis, which yielded frag- 
ments  of 24,  32,  35,  and  55  kD  (Fig.  1  C  and  data  not 
Table  1.  Nuclear Autoantigens  Cleaved during CD95-mediated Apoptosis 
Autoantigen  Associated functions  Proteolytic fragments 
DNA topoisomerase I  Modification of DNA topology  70 kD 
DNA topoisomerase II  Modification of DNA topology; anchoring chromatin to nuclear matrix  Multiple (125-160 kD) 
Lamin B  Nuclear envelope formation; anchoring chromatin to nuclear matrix  45 kD 
NuMA  Mitotic spindle formation; anchoring chromatin to nuclear matrix  160,  180 kD 
PARP  DNA repair; interaction with chromatin in the nuclear matrix  85 kD 
UBF/NOR-90  RNA pol I transcription; post-mitotic nucleolar organization  Multiple (24-55 kD) 
U1-70 kD  pre-mRNA splicing;  associated  with the nuclear matrix (?)  40 kD 
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set  of  autoantigens  during 
CD95-mediated apoptosis of  Jur- 
kat cells. Representative blots of 
control  and  apoptotic  lysates 
probed with various human  au- 
toimmune sera are shown. Intact 
proteins  are  indicated  by  lines, 
whereas  proteolytic  fragments 
are  indicated by arrows. Num- 
bers to the right of each blot rep- 
resent relative molecular mass in 
kD.  The  anti-Sin  serum  also 
contained  antibodies  to  U1-70 
kD.  The anti-U1-70  kD serum 
contained  antibodies to  a  non- 
cleaved protein of 36 kD. 
shown).  Other  non-cleaved  autoantigens  included  SSA/ 
Ro,  SSB/La,  pS0  coilin,  ribosomal  proteins  P0,  P1,  and 
P2,  mitochondrial  autoantigens  PDCE2,  X,  OGDC, 
BCOADC,  and Elot,  and tRNA  synthetases Jo-1  (histidyl) 
and PL12  (alanyl)  (Fig.  1 and data not shown). 
Relative  Kinetics of Nuclear Autoantigen Cleavage after Induc- 
tion of CD95-mediatedApoptosis.  To  gain  some  insight 
into the relative sequence ofproteolytic events during apop- 
tosis we examined the kinetics of autoantigen  cleavage after 
addition  of anti-CD95  antibody  to Jurkat  cells.  Substantial 
cleavage of PARP and NuMA was already detectable by 1 h 
(Fig.  2 A). These cleavages occurred before the appearance 
of appreciable  numbers  of apoptotic  cells  in  the  cultures. 
NuMA  cleavage  first yielded  two  fragments  of ~190  and 
180  kD,  respectively.  The  190-kD  fragment  disappeared 
after 3  h  and  a  new fragment  of~160  kD  began  to accu- 
mulate.  A  short time-course experiment showed that PARP 
cleavage was already evident within  15 rain of induction  of 
apoptosis, whereas the cleavage of NuMA began shortly af- 
terwards  (data not shown).  Lamin B  was also targeted rela- 
tively  early during  apoptosis,  as judged  by the  appearance 
of a  small  amount  of the  46-kD  fragment  at  1  h.  This 
cleavage  progressed  steadily  and  reached  near  completion 
by 7 h  (Fig. 2  C). U1-70 kD cleavage occurred very rapidly 
between  1-2  h  after induction  of apoptosis since very low 
amounts of intact 70 kD were detected after 2 h  (Fig. 2  D). 
Cleavage  of DNA  topo  I  was  first visible by 2  h  and  was 
characterized  by  the  appearance  of 70-  and  60-kD  pro- 
teolytic fragments. The 60-kD fragment was no longer de- 
tected after 3 h, whereas the amount of the 70 kD continued 
increasing  as  apoptosis  progressed  (Fig.  2  E).  Substantial 
cleavage  of the  protein  was  not  obvious  until  appreciable 
number  of apoptotic  cells  (50--60%)  had  accumulated  by 
5-7 h.  Cleavage ofDNA  topo II (both the ~x and  [3 forms) 
was  evident  at  3  h,  as  indicated  by  the  decrease  in  the 
amount  of the  intact  proteins,  and by 7  h  the  protein  was 
completely degraded  into  several smaller fragments  (Fig.  2 
F).  Cleavage  of UBF  was  first  detected  at  2  h  by the  ap- 
pearance  of a weak 58-kD  band  (Fig.  2  G)  and progressed 
to  generate  fragments  of 24,  32,  and  35  kD.  None  of the 
Sm components were cleaved (Fig.  2 H). 
Cleavage of DNA  Topo I Is Specifically Associated with Apop- 
tosis.  The results presented above indicate that DNA topo 
I  is  a  major substrate  targeted  by proteases  during  CD95- 
mediated  apoptosis.  Since  it  has  been  unclear  in  previous 
studies whether DNA  topo I  cleavage is specifically associ- 
ated  with  apoptosis  (9,  13,  14),  we  performed  additional 
experiments  aimed  at  demonstrating  this  association.  We 
first examined whether DNA  topo I  cleavage could be in- 
hibited  under  conditions  where  CD95-mediated  apoptosis 
was inhibited. Jurkat cells were preincubated  for 1 h  in the 
presence of 10  p,M of a peptide  inhibitor  (Z-Val-Ala-Asp- 
fluoromethylketone;  Z-VAD-frnk)  of ICE/CED-3  proteases. 
Cells were then induced to undergo apoptosis by incubation 
with anti-CD95  mAb. Apoptosis was significantly inhibited 
in  cells  preincubated  with  Z-VAD-fmk  (data  not  shown). 
767  Casiano  et al.  Brief Definitive Report Figure  2.  Kinetics of autoantigen cleavage after 
addition of anti-CD95 n~Ab to Jurkat cells. Intact 
proteins are indicated by lines, whereas proteolytic 
fragments are indicated by arrows. Numbers to the 
right of each blot represent relative molecular mass 
in kD. Results are representative of two indepen- 
dent experiments conducted under similar condi- 
tions. 
Lysates from cells  treated  with  anti-CD95  mAb alone  re- 
vealed  substantial  cleavage  of PARP  and  DNA  topo  I, 
whereas lysates from cells  treated  with  the antibody in the 
presence  of Z-VAD-fmk  exhibited  partial  inhibition  of 
PAP,  P  cleavage  and  complete  inhibition  of DNA  topo  I 
cleavage (Fig.  3). We also determined whether diverse apop- 
tosis-inducing  stimuli  promoted  cleavage  of DNA  topo  I. 
Substantial  cleavage of DNA  topo  I  into  the  70-kD  frag- 
ment was detected  after a  12 h  exposure  of  Jurkat  cells  to 
apoptosis-inducing concentrations of C2-ceramide,  etopo- 
side  (VP-16),  actinomycin D,  cycloheximide,  and  stauro- 
sporine  (Fig.  4  A). Extensive cleavage of DNA topo I was 
also  observed  6.5  h  after  induction  of apoptosis  in  AI.1 
cells  with  anti-CD3  mAb  (Fig.  4  /3). Typically,  morpho- 
logical  characteristics  of  apoptosis  appear  in  these  cells 
within 3-4 h  of incubation with the antibody, and 50-80% 
of the  cells  are  apoptotic  within  7-10  h  (11).  In  contrast 
with the results obtained in Jurkat cells  (see  Figs.  1, 2  E, 3, 
and 4 A) this  cleavage resulted in the generation  of several 
proteolytic products ranging from 24 to 48 kD in addition 
to the 70-kD fragment, suggesting the possibility that vari- 
ous proteases might be involved in the cleavage of this pro- 
tein in A1.1  cells. 
lar degradation.  Although the exact role of the proteolytic 
cleavages described here in the execution phase of apopto- 
sis remains  to be  established,  it is noteworthy that most of 
the  cleaved  autoantigens  are  involved in  ensuring  the  in- 
tegrity and proper conformation of DNA in the nucleus or 
are  associated  with  the  nuclear  matrix  (Fig.  1;  Table  1). 
This  suggests  the  possibility  that  some  of these  cleavages 
could contribute to the collapse of nuclear matrix structure 
Discussion 
These  findings  underscore  the  use  of human  autoanti- 
bodies as valuable tools for defining the various proteolytic 
events associated with apoptosis and strengthen  the notion 
that this cell death process is accompanied by selective pro- 
teolysis of key substrates  and not by generalized intracellu- 
Figure 3.  Inhibition ofproteolytic cleavage  of PARP and DNA topo 1 
under conditions where apoptosis is inhibited. Jurkat cells were pre-incu- 
bated in the presence or absence Z-VAD-fillk (10 b~M) for 30 rain before 
addition of anti-CD95 antibody. Nitrocellulose blots of cell lysates from 
control cells, cells treated with anti-CD95 mAb alone for 7 tl, and cells 
pre-incubated with Z-VAD-fmk and then treated with anti-CD95 mAb 
for 7 h, were reactive with human autoantibodies to PARP and I)NA 
topo I. 
768  Autoantigen Cleavage during CD95-mediated Apoptosis Figure 4.  Cleavage  ofDNA topo I during apoptosis induced by differ- 
ent stimuli. (A) Cleavage of DNA topo I in Jurkat cells induced to un- 
dergo apoptosis by incubation with anti-CD95 mAb for 7 h, or by incu- 
bation with C2-ceramide (40 p~M), cycloheximide (75 ~M), actinomycin 
D (10 ~M), etoposide (150 ~M), and staurosporine (2 }xM) for 12 h. (B) 
Cleavage of DNA topo  I during anti-CD3-induced  apoptosis of A1.1 
cells. 
thereby facilitating chromatin degradation and nuclear frag- 
mentation. 
This  study  demonstrates  conclusively  that  UBF,  DNA 
topo I, and DNA topo II are major targets ofproteases dur- 
ing  CD95-mediated  apoptosis.  The  apoptotic  degradation 
of DNA  topo  I and DNA  topo II had been reported in an 
earlier study but  the  cleavage products  were  not  identified 
and  the  cleavage  kinetics  were  not  established  (13).  Two 
subsequent  studies  suggested  that  DNA  topo  I  cleavage 
during apoptosis is minimal or non-specific  (9, 14). We ob- 
served,  however,  that  DNA  topo  I  cleavage  was  specific, 
substantial,  and  tightly  coupled  to  apoptosis  since  it  could 
be inhibited  under conditions where CD95-mediated  apop- 
tosis  was  blocked,  was  detected  during  apoptosis  induced 
by a variety of stimuli,  and was not observed in control ly- 
sates. These discrepancies could be attributed to differences 
in  the  kinetics  of the  apoptosis  systems and  in  the  experi- 
mental conditions  employed to induce apoptosis. 
The  observed  differences  in  the  relative  kinetics  of au- 
toantigen  cleavage  suggests  either  differential  accessibility 
or activation of distinct proteases during the cell death pro- 
cess. The identity of the protease(s)  responsible for most of 
these  cleavages  remains  unclear,  although  ICE/CED-3 
proteases have been shown to cleave PARP and U1-70 kD 
in  vitro  (2-4).  The  cleavage  of NuMA  and  DNA  topo  I 
into  discrete  fragments implies  that  they  were  targeted  by 
proteases  cleaving at specific sites,  whereas  the  cleavage  of 
DNA  topo  II  and  UBF  into  multiple  fragments  suggests 
that various proteases might be targeting these proteins. Al- 
though  it  is  possible  that  DNA  topoisomerases  and  UBF 
were cleaved by lysosomal proteases during advanced stages 
of CD95-mediated  apoptosis, the fact that several other in- 
tracellular  proteins  remained  intact  during  these  stages 
clearly  indicated  a  high  degree  of specificity  in  the  pro- 
teolytic  targeting of these  autoantigens.  It would  be of in- 
terest  to  determine  whether  ICE/CED-3  proteases  also 
participate  in  the  late  cleavage  events  involving  the  DNA 
topoisomerases and UBF. 
It  has  been  suggested  that  apoptosis-associated  cleavage 
may  enhance  the  immunogenicity  of autoantigens  by  re- 
vealing  immunocryptic  epitopes  that  are  not  efficiently 
generated  during  antigen  processing  (9).  The  fact  that 
many proteins  that are frequently targeted by autoantibod- 
ies in human systemic autoimmune  diseases are not cleaved 
during  apoptosis  (9  and  this  study)  suggests  that this  puta- 
tive mechanism, if operational,  may be limited only to spe- 
cific  autoantigens.  The  presence  of non-cleaved  autoanti- 
gens  in  apoptotic  bodies  or  blebs,  such  as  SSA/Ro  and 
SSB/La (15), suggests that alternative mechanisms might be 
operating to render released intracellular antigens immuno- 
genic.  It  is  possible  that  autoantibody  responses  could  be 
amplified and maintained upon repeated stimulation by an- 
tigens  due  to unregulated  or aberrant  apoptosis,  prolonged 
necrosis,  defective  phagocytic  processing  and  presentation 
of debris from dying cells,  or even antigen  overexpression. 
It would be important  not only to assess  the immunogenic 
potential  of subcellular  particles  and  of proteolytic  frag- 
ments released during cell death but also to investigate pos- 
sible  defects  leading  to  aberrant  apoptosis  or  phagocyte 
function,  or  antigen  overexpression  in  systemic  autoim- 
mune diseases. 
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